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são pistas importantes para um diagnóstico preco-
ce. A disfagia é um sintoma frequente no decurso
da doença. A biópsia muscular pode apresentar al-
terações miopáticas crónicas, infiltrados linfocíti-
cos envolvendo fibras não-necróticas, «rimmed va-
cuoles» e acumulação de proteínas amilóides. Per-
manece a dúvida sobre se a MCIe é primariamen-
te uma miopatia inflamatória imuno-mediada ou
se se trata de uma miopatia degenerativa com um
componente inflamatório associado. Esta revisão
descreve a epidemiologia e as características clíni-
cas da doença, bem como a sua abordagem tera-
pêutica e conceitos genéticos e etiopatogénicos
actuais. Apesar das mais recentes descobertas, em
muitos aspectos, a MCIe permanece um mistério
por resolver.
Palavras-chave: Miosite de Corpos de Inclusão;
Miosite; Miopatia; Inflamação; Degeneração.
Introduction
Sporadic IBM is traditionally classified as an idio-
pathic inflammatory myopathy, along with poly-
myositis (PM) and dermatomyositis (DM).1 The his-
topathologic changes in sIBM were first described
in the mid-1960s,2,3 although the disorder was not
distinguished from PM and named until 1971.4
sIBM is now considered the commonest acqui-
red muscle disease among those aged over 50 years.
It is a severely disabling disorder, still without effec-
tive treatment.5 Characteristically, sIBM causes a
selective pattern of muscle weakness, predomi-
nantly involving the forearm flexor and quadriceps
femoris muscles early in the disease course.6 This
leads to loss of manual control, impaired mobility
and a propensity to fall. There is often subsequent
involvement of the distal leg, proximal arm, and
pharyngeal muscles resulting in dysphagia.6-10 Be-
cause of the limited awareness among medical
practitioners of its existence, the protracted clini-
cal course, and histological similarity with other
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Abstract
Sporadic inclusion body myositis (sIBM) is consi-
dered to be the most common acquired muscle di-
sease associated with aging. It is a disabling disor-
der still without effective treatment. sIBM causes
weakness and atrophy of the distal and proximal
muscles. Involvement of quadriceps and deep fin-
ger flexors are clues to early diagnosis. Dysphagia
in the course of the disease is common. Muscle
biopsy shows chronic myopathic features, lym-
phocytic infiltration invading non-necrotic fibbers,
rimmed vacuoles and accumulation of amyloid-re-
lated proteins. It remains uncertain whether sIBM
is primarily an immune-mediated inflammatory
myopathy or a degenerative myopathy with an as-
sociated inflammatory component. This review
describes the epidemiology and clinical features of
the disease as well as the current genetic and pa-
thogenic concepts and therapeutic approaches.
Despite recent clues, in many respects sIBM re-
mains an unsolved mystery.
Keywords: Inclusion Body Myositis; Myositis; Myo-
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Resumo
A forma esporádica da miosite de corpos de inclu-
são (MCIe) é considerada a mais frequente doença
muscular adquirida associada com o envelheci-
mento. É uma doença incapacitante ainda sem tra-
tamento eficaz. A MCIe provoca atrofia e fraqueza
tanto de grupos musculares proximais como dis-
tais. O envolvimento selectivo dos músculos qua-
drícipete femoral e flexores profundos dos dedos
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myopathies, the diagnosis of sIBM is commonly
delayed and initially inaccurate.11,12
The primary cause of sIBM is unknown, but is
thought to involve a complex interplay between
environmental factors, genetic susceptibility and
aging. The recognition of proteinaceous deposits in
sIBM triggered an evolving body of evidence distin-
guishing this disorder from the idiopathic inflam-
matory myopathies.13 sIBM is enigmatic in its com-
bination of inflammatory and degenerative featu-
res that persist from the early stages of the disease
to its most advanced phase. The inflammatory
changes include upregulation of proinflammatory
chemokines14 and cytokines15 in an inflammatory
environment that attracts clonally expanded, cyto-
toxic CD8+ T-cells. These attack myofibres that ove-
rexpress major histocompatibility complex (MHC)
class I, which is not constitutively expressed by ske-
letal muscle.16,17 The second hallmark of sIBM is the
accumulation of aberrant molecules, notably 
β-amyloid, within the myofibres.18 Other molecules
associated with cellular stress and degeneration are
also overexpressed in sIBM.19 Cytochrome c oxida-
se (COX) deficient fibres and ragged-red fibres re-
flect mitochondrial impairment.20 The relationship
between T-cell invasion and other histopathologi-
cal changes in muscle fibres is not known, and it re-
mains uncertain whether sIBM is primarily an im-
mune-mediated inflammatory myopathy or a de-
generative myopathy with an associated inflam-
matory component.21
This review describes the epidemiology and cli-
nical features of the disease as well as the current
genetic and pathogenic concepts and therapeutic
approaches. Despite recent clues, in many respects
sIBM remains an unsolved mystery.
Epidemiology
It has been estimated that sIBM represents 16-28%
of patients with idiopathic inflammatory myosi-
tis.22,23 However, the true frequency may be higher,
and apparently exceeds that of PM, frequently ini-
tially misdiagnosed in sIBM patients.24
The prevalence of sIBM differs between diffe-
rent populations and ethnic groups.25 It has been
estimated to be 4.9 per million population in the
Netherlands11 (adjusted to 16.0 per million above 50
years of age), 9.3 per million in Western Australia12
(adjusted to 35.5 per million above 50 years of age)
and 10.7 per million in Connecticut, United States
of America (USA) (adjusted to 28.9 per million abo-
ve 45 years of age).8 These figures are almost cer-
tainly an underestimate and the true prevalence of
sIBM may be substantially higher than previously
thought. 
In a recent population-based study in Minneso-
ta, USA,26 nine patients with sIBM provided an in-
cidence estimate of 7.9 per million per year and a
prevalence rate of 70.6 per million. These are the
highest rates reported for sIBM to date. The inci-
dence and prevalence of sIBM exceeded figures for
PM, for which the same authors reported an inci-
dence of 4.1 per million per year and a prevalence
of 34.5 per million, while previous studies in PM es-
timated an incidence from 5.5 to 10 per million.27,28
A follow-up survey in Western Australia29 has re-
cently been published, and the previously repor-
ted prevalence of 9.3 per million12 has been upda-
ted to 14.9 per million (adjusted to 51.3 per milli-
on above 50 years of age). The authors also report
a high rate of initial misdiagnosis and a large mean
time to diagnosis (5.2 years), again suggesting that
even the latest prevalence figures may be an unde-
restimate and emphasising the need to increase
the level of awareness about the condition among
the medical community.
Larger, multicentre trials are needed to define
the epidemiology of sIBM among different geo-
graphic regions and ethnic groups and to determi-
ne the contribution of different genetic or environ-
mental factors to these variations.
Genetics
Existing evidence for genetic susceptibility in sIBM
has been based on candidate gene studies. The ra-
rity of the condition has precluded the use of more
robust genetic methods such as twin studies, who-
le genome screening, and transmission disequili-
brium testing. More recently, microarray techno-
logy has provided interesting data on sIBM.
So far, MHC associations provide the strongest
evidence for a genetic component in sIBM. The
strong association of HLA-DR3 and the extended
8.1 ancestral haplotype (AH) (characterised by
HLA-A*01, -B*0801, -DRB1*0301, -DQB1*0201, 
-DQA1*05) with sIBM was first reported in Austra-
lian patients30 and then confirmed in Dutch, Ger-
man and North American cohorts.31-34 The suscep-
tibility region has been confined to between PBX2
and HLA-DRB.33 A few genes within this region
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have been suggested as candidates for further
study, including BTNL2 (butyrophilin-like MHC
class II-associated gene, which is expressed in ske-
letal muscle), TSBP (testis-specific basic protein),
NOTCH4 (a transmembrane receptor that regula-
tes cell fate decisions), GPSM3 (a predicted gene
with an unknown function previously known as
G18), and AGER (advanced glycosylation end pro-
duct-specific receptor, a member of the immuno-
globulin superfamily of cell-surface molecules pre-
viously known as RAGE).33,35
In addition to the 8.1 AH, other AH alleles have
been associated with sIBM. Association with HLA-
-DR52 in a North American population36 probably
reflected the association with the 8.1 AH, although
DR52 is also part of a number of other AHs. AH
35.2 (defined by DR1, BTNL2(E6)*2, PBX2*T,
AGER*T, and B35) has been suggested to confer
susceptibility to sIBM in Caucasians33 and AH 52.1
(defined as HLA-A*2402, Cw*1202, B*5201,
DRB1*1502, DQA1*0103, DQB1*0601) has been
suggested to confer susceptibility to sIBM in Japa-
nese37 (particularly HLA-B*5201 and HLA
DRB1*1502). In contrast, the DRB1*04-DQA1*03
and DQA1*0201 alleles have been reported as pro-
tective in a North American population38 and the
HLA-DR53 allele in a Dutch population.34
In addition to MHC associations, polymor-
phisms and mutations in genes encoding the de-
posited proteins have also been investigated, but
results have been inconclusive. These studies have
included β-amyloid precursor protein (βAPP),39
prion protein,40-42 apolipoprotein E (ApoE)43,44 and
α-1-antichymotrypsin (α1ACT).43
Mitochondrial mutations45-47 have also been in-
vestigated. Multiple mitochondrial deoxyribonu-
cleic acid (mtDNA) deletions have been demons-
trated in different muscle fibres in sIBM,46 and can
differ even between different segments of the same
fibre.45,47 In addition, segmental duplications and
depletion of mtDNA also occur.47 Oldfors et al20 in-
vestigated the POLG1, ANT1 and C10orf2 mito-
chondrial encoded genes, as variants of these ge-
nes had previously been associated with multiple
mtDNA mutations, and did not find any mutations
in five sIBM patients.
In sIBM and PM muscle, recent microarray stu-
dies demonstrated high immunoglobulin gene ex-
pression.48 As immunoglobulin genes are only
transcribed in B cells and their progeny, this fin-
ding appeared paradoxical given that sIBM mus-
cle has been known to contain abundant cytotoxic
T cells and reported to contain few or no B cells.49,50
This discrepancy was clarified with further immu-
nohistochemical studies that showed few B cells as
defined by the expression of CD20, but abundant
CD138+ plasma cells, effector antibody-secreting
cells derived from B cells after antigen stimulation
and differentiation.
It was shown that the B-cell immunoglobulin
repertoire in sIBM, and also in PM and DM, has de-
veloped as a consequence of antigen stimulation.51
As plasma cells produce antigen-specific antibo-
dies in sIBM, these autoantibodies may be used as
reagents to identify the muscle antigens to which
they are directed. Using mass spectrometry-based
proteomic methods this approach has led to the
suggestion of muscle αB-crystallin as an autoanti-
gen in sIBM.52 The significance and generalization
of this finding, published in abstract format, re-
mains to be determined.
Microarray studies of sIBM and PM also predic-
ted the presence of myeloid dendritic cells, the im-
mune system’s professional antigen-presenting
cell central to the development of adaptive immu-
ne responses. Bioinformatic pathway analyses sug-
gested that local intramuscular antigen presenta-
tion by myeloid dendritic cells was occurring.53
These cells were subsequently confirmed by im-
munohistochemistry in large numbers in most
sIBM and PM muscle biopsy samples studied,54 ha-
ving been recognized previously in PM55 but not in
sIBM.
Clues for further candidate gene studies are ari-
sing from the progress that has been made over
the last decade in identifying genes associated with
hereditary inclusion body myopathies and other
vacuolar myopathies that have features similar to
sIBM, as well as gene expression profiling studies.
The identification of susceptibility genes is funda-
mental to elucidating the pathogenesis of sIBM
and may provide clues to the development of tar-
geted therapies.
Familial Inclusion Body Myositis
Multiple case reports of two or more siblings 
being affected in the same family,56-60 and rare re-
ports of affected twins61 suggest a familial predis-
position for developing sIBM. 
The familial occurrence of such a rare disease
highlights the importance of genetic predisposi-
tion in the aetiopathogenesis of sIBM. These cases
have been named familial inclusion body myosi-
tis (fIBM) because of the similarities with sIBM.
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The only exception is the family reported by Nau-
mann,56 where onset was earlier and with promi-
nent weakness in finger and arm extensors. fIBM
has been associated with DR3 (DRB1*0301/
/0302)57,60 and DR15(2)/DR4 (DRB1*1502/0405).59
In conclusion, sIBM and fIBM share the same
clinical, biological, magnetic resonance imaging
(MRI) and histological features, and possibly gene-
tic markers (DR3).60 They differ from the hereditary
inclusion body myopathies, which will be discus-
sed in the next section of this review.
Hereditary Inclusion Body Myopathies
Askanas and Engel introduced the term “hereditary
inclusion body myopathies” (hIBM) in 199362 in or-
der to specify hereditary muscle diseases with pa-
thologic features that strikingly resemble those of
sIBM, including rimmed vacuoles and intracyto-
plasmic and intranuclear tubulofilamentous in-
clusions. They differ from sIBM with an earlier age
of onset, negative MHC class I staining and the ra-
rity of lymphocytic inflammation, hence the term
“myopathy” instead of “myositis”. The hIBM en-
compass several autosomal-recessive and autoso-
mal-dominant syndromes of progressive muscle
weakness, with various clinical presentations. The
hIBM can be grouped by their mode of inheritan-
ce and genetic mutation.63 They may provide im-
portant clues for the aetiopathogenesis of sIBM
and will be briefly reviewed.
Hereditary Inclusion Body Myopathy 2 (hIBM2;
Nonaka; DMRV): Recessive
Hereditary inclusion body myopathy 2 (hIBM2;
OMIM 600737) was likely first recognized in Japan.
In 1981, Nonaka et al 64,65 described an autosomal
recessive “distal myopathy with rimmed vacuoles”
(DMRV) in the Western literature. Argov et al 66 pu-
blished nine cases from four Jewish families of Ira-
nian descent of autosomal recessive “rimmed va-
cuole myopathy” sparing the quadriceps. A larger
series of Iranian Jews with the same disorder was
subsequently published by a group from Tel Aviv67
and found in other ethnic groups.68 With the iden-
tification of the causative gene, it became apparent
that Nonaka/DMRV and the “rimmed vacuole
myopathy” described by Argov et al 66 were the
same disease.69
The disorder is characterised by progressive dis-
tal and proximal weakness that starts in young
adulthood, usually in the second half of the third
decade, with a predilection for distal limb muscles.
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The striking feature is quadriceps femoris sparing
even at advanced stages of the disease. However,
based on results of molecular genetic testing, it is
now recognized that quadriceps sparing is not a
constant feature since some individuals without
this finding have been identified.70 Affected indivi-
duals are usually wheelchair bound about 20 years
after onset.
GNE, encoding UDP-N-acetylglucosamine 
2-epimerase/N-acetylmannosamine kinase
(chromosomal locus 9p12-p11), is the only gene
known to be associated with hIBM2.71 The enzyme
is best characterised for regulation of the rate-li-
miting epimerase step in sialic acid biosynthe-
sis.72,73 hIBM2 is inherited in an autosomal recessi-
ve manner.
Hereditary inclusion body myopathy with joint 
contractures and ophthalmoplegia (hIBM3):
Dominant
Hereditary inclusion body myopathy with joint
contractures and ophthalmoplegia (hIBM3; OMIM
605637) was first reported in 1998.74 In a large fami-
ly with 19 affected cases with autosomal dominant
inheritance, the characteristic clinical features
were congenital joint contractures, which norma-
lized during early childhood, external ophthalmo-
plegia and proximal muscle weakness. The clinical
course was non-progressive in childhood, but most
adult cases experienced deterioration of muscle
function, starting from 30 to 50 years of age. 
The disease was subsequently mapped to a 
2-Mb chromosomal region in 17p13.1,75 and then
found to be due to a mutation in the myosin heavy
chain IIa (MHCIIa) gene (Glu706-Lys).76 Myosin
type IIa is the main myosin isoform in type 2A fi-
bres, the type of fibres frequently abnormal in
hIBM3, whereas other fibre types usually appear
normal in this disease.
Inclusion body myopathy with dementia and
Paget disease of bone (IBMPFD): Dominant
Inclusion body myopathy (IBM) with early-onset
Paget’s disease of the bone (PDB) and frontotem-
poral dementia (FTD) is a rare autosomal domi-
nant multisystem disorder, first described in 1982,77
characterised by a variable expression of the three
main features and thus designated as IBMPFD
(OMIM 167320). The mean age of onset of IBM,
PDB and FTD is around 44, 42 and 54 years, respec-
tively.78 The age-related, incomplete penetrance of
the three major signs, as well as the variable invol-
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vement of other systems, allow framing a wide
spectrum of illnesses in the IBMPFD presentation. 
After linkage mapping of the IBMPFD locus on
chromosome 9p13.3-p12,78 missense mutations in
the gene encoding for valosin-containing protein
(VCP) were found in linked families originating
from either Europe or North America.79 VCP is an
ubiquitous member of the AAA+ (ATPase associa-
ted with a variety of cellular activities) family, a
group of enzymatic chaperones involved in seve-
ral cellular processes such as membrane fusion/
/transport, stress response, reconstitution of endo-
plasmic reticulum/Golgi, protein degradation and
protein folding, DNA replication, apoptosis and
cell cycle control.80
IBMPFD is inherited in an autosomal recessive
manner. Nevertheless, despite the simple mode of
inheritance, counselling is difficult because of the
variable involvement of multiple systems, varia-
ble age of onset of the cardinal signs and possible
occurrence of cognitive decline.
Hereditary Inclusion Body Myopathy 1 (hIBM1):
Dominant
Hereditary Inclusion Body Myopathy 1 (hIBM1) is
no longer considered to be a distinct entity. Pati-
ents who were considered to have hIBM1 are now
included in the myofibrillar myopathy group.
Distal myopathies and Myofibrillar myopathies
The imprecise term “distal myopathy”81 is undesi-
rable. Some previously designated distal myopa-
thies are indeed hIBM. Myofibrillar myopathies82
(OMIM 601419) are characterised by slowly pro-
gressive weakness that can involve both proximal
and distal muscles. Both are groups of genetically
determined myopathies that can be part of the dif-
ferential diagnosis of sIBM/hIBM but because con-
sidered out of the scope of this review, they will not
be discussed in detail.
Aetiopathogenesis
Pathologically, sIBM is characterised by an intra-
muscular inflammatory component of variable se-
verity, with a predominance of clonally expanded83
CD8+ T-cells and upregulation of MHC class I an-
tigen, including in non-necrotic muscle fibres.84
The degenerative component is characterised by
rimmed vacuole formation, and intracellular pro-
teinaceous deposition as tubulofilamentous and
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eosinophilic inclusions.85 The protein inclusions
comprise a number of proteins related to neurode-
generative diseases, including β-amyloid and
βAPP,86 phosphorylated tau,87 α1ACT,88 α-synu-
clein,89 prion protein90 and ApoE.91 Ubiquitins,92
aβ-crystallin,19 parkin,93 copper zinc superoxide dis-
mutase,94 manganese superoxide dismutase,95
apoptotic regulators (Bcl-2, Bcl-x and BAX)96 and li-
poprotein receptors97 have also been described as
overexpressed in sIBM. Finally, mitochondrial in-
volvement is evidenced by non-necrotic COX defi-
cient fibres and ragged-red fibres.20 Histopathology
features will be detailed in the next section of this
review.
Recent research has highlighted the importance
of both the inflammatory and the degenerative pro-
cesses in the pathogenesis of sIBM, but the man-
ner of interaction of these pathological mecha-
nisms remains uncertain. On the one hand, local
expression of proinflammatory chemokines14 such
as CC- or CXC-chemokine ligands (CXCL)-9,98,99
CXCL-10,98,99 CCL-2,100 CCL-3101,102 and CCL-4,102 and
cytokines15 such as interleukin-1β103,104 (IL-1β), 
tumor necrosis factor alpha103-105 (TNF-α), interfe-
ron gamma98 (IFN-γ) and transforming growth fac-
tor-β104 (TGF-β) could be an early upstream patho-
genic event linking the inflammatory and degene-
rative component of sIBM, as hypothesized by Da-
lakas.5 Proinflammatory cytokines are very effective
inducers of MHC class I expression in human myo-
tubes.106 It has been suggested that MHC class I ex-
pression exerts a stressor effect on the endoplasmic
reticulum causing NFκB upregulation,107 leading to
further enhancement of MHC class I antigen as-
sembly and cell membrane expression,107 which
may in turn lead to a self-sustaining T-cell res-
ponse.108 Proinflammatory cytokines (particularly
IL-1),109,110 as well as NFκB111 have been shown to in-
crease βAPP transcription, which results in increa-
sed β-amyloid production. This could trigger a cas-
cade of endoplasmic reticulum stress, proteasome
dysfunction, and protein accumulation, particu-
larly in an aged cellular environment which might
include mitochondrial DNA mutations, proteaso-
mal impairment and an attenuated “Heat Shock
Response”.112 A relationship between the inflamma-
tory and degenerative processes is supported by
recent observations of Schmidt et al 113 in which hu-
man myotubes in vitro demonstrated accumulati-
on of βAPP in response to exposure to the inflam-
matory mediators IL-1β and TNF-α. Schmidt et al113
also found that in sIBM muscles there was a linear
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relationship between the mRNA level of cytokines
and chemokines, and that of βAPP, tau, and ubiqui-
tin. Supporting this interplay between inflamma-
tory and degenerative molecules, Kitazawa et al,114
using an sIBM-transgenic mouse model, found
that acute and chronic inflammation induced by
lipopolysaccharide increased the steady-state level
of βAPP and phosphorylated tau in skeletal muscle
by inducing glycogen synthase kinase-3β (GSK-3β),
a tau kinase. The cytokines IL-1β, IL-6 and TNF-α
upregulated GSK-3β, whereas antibodies against
them effectively attenuated the inflammation-in-
duced tau phosphorylation. The GSK inhibitor, li-
thium, had a similar effect and the authors propo-
sed that suppression of inflammation in sIBM may
slow disease progression. However, evidence
against this theory includes previous unsuccessful
clinical trials of immunotherapies. Even where his-
tological evidence of inflammation was reduced,
this was not accompanied by clinical improve-
ment. Furthermore, transgenic mice overexpres-
sing MHC Class I apparently lack intracellular de-
generative protein deposition.
Epiphenomenal inflammation is demonstrated
by other diseases of skeletal muscle, notably fas-
cioscapulohumeral dystrophy and it is possible
that the degenerative aspects of sIBM, notably 
β-amyloid accumulation (due to overproduction
or abnormalities in processing βAPP) are early up-
stream events as proposed by Askanas and Engel.18
Cell injury then results from direct toxicity of pro-
teins including β-amyloid, as well as from endo-
plasmic reticulum stress, oxidative stress, and a se-
condary T-cell response to peptides derived from
the accumulating proteins, supported by the acti-
vation of the proinflammatory transcription factor
NFkB. Indeed, overexpression of βAPP in the ske-
letal muscle of transgenic mice, causes muscle we-
akness and atrophy.115-118 This is accompanied by an
inflammatory infiltrate which, where β-amyloid42
(an isoform of β-amyloid) is selectively augmented,
is by CD8+ lymphocytes.117 In vitro, overexpression
of βAPP and accumulation of β-amyloid and/or
tau protein functionally impairs muscle cells, their
contractility and induces features similar to myo-
fibres in sIBM, including formation of vacuoles,
intracellular protein aggregates, mitochondrial
dysfunction and proteasomal inhibition.119,120 Al-
terations in sarcoplasmic reticulum Ca2+ release
and in skeletal muscle contractility have also been
associated with a deleterious β-amyloid modula-
tion of the ryanodine receptor Ca2+ release chan-
nels in sIBM mice.121 Since Ca2+ handling is a ma-
jor determinant of force generation in skeletal
muscle, amyloid-mediated changes in Ca2+ ho-
meostasis may also have a role in sIBM. Accumu-
lations of β-amyloid and even βAPP are toxic to the
muscle as well as other cells in vivo and in vi-
tro.122,123 Interestingly, type 2 myofibres (fast, anae-
robic fibres) appear particularly susceptible to
their detrimental effects and deposition. It has
been postulated that in sIBM muscle fibres, amy-
loid toxicity may be less attributable to insoluble
aggregates of β-amyloid, but rather to an intracel-
lular toxicity of its soluble oligomers and protofi-
brils.18
The overexpression of other cell stress and de-
generation-associated molecules such as the small
heat-shock molecule aβ-crystallin and ubiquitin,19
a tagging molecule for proteasomal degradation
of abnormal proteins, would accompany the dege-
nerative process. Crucially, since intracellular 
accumulation of aberrant protein appears to be
both a consequence and a trigger of proteasomal
dysfunction, this process is likely to be self-sustai-
ning. 
Regarding the mitochondrial changes, it has
been proposed that mutations are likely to occur
during the repair of mtDNA damage induced by
oxidative stress. The mitochondrial changes could
also be related to abnormal βAPP processing, as
mitochondrial abnormalities have been demons-
trated in muscle cultures overexpressing βAPP,119 or
to the effects of pro-inflammatory cytokines, as
muscle cultures treated with IL-1β also demonstra-
te mitochondrial abnormalities.124 The clinical sig-
nificance of the mitochondrial abnormalities in
sIBM is still unclear, particularly given that in vivo
31P magnetic resonance spectroscopy studies have
not shown any evidence of impaired muscle oxi-
dative metabolism.125,126 However, the numbers of
fibres showing these changes in muscle biopsies
are usually in excess of what would be expected for
the patient’s age,45,127 and in some instances are
more numerous than in cases of mitochondrial
myopathy where they would be considered to be
pathogenic. Moreover, in normal aging mtDNA
mutations have been associated with muscle fibre
atrophy and breakage, and are thought to be an
important factor in the sarcopenia of aging.128 As
suggested by Oldfors et al 20 it is therefore possible
that the mtDNA mutations and associated respi-
ratory deficiency may contribute to the atrophy of
muscle fibres and muscle weakness in sIBM. Inte-
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restingly, the protein DJ-1, proposed to act as an
antioxidant and to be an important mitochondri-
al protective agent, has been shown to be increa-
sed and highly oxidized in sIBM patients.129
The ultimate cause of the postulated proinflam-
matory cytokine expression or β-amyloid overpro-
duction is still unknown and multiple genetic fac-
tors may contribute to the development and pro-
gression of sIBM. Although the cytoplasmic and
nuclear tubulofilamentous inclusions in muscle fi-
bres were first thought to be viral in origin, and
subsequent immunohistochemical studies sug-
gested the possibility of an aberrant mumps vi-
rus,130 this hypothesis was not supported by sub-
sequent studies.131,132 However it does not preclu-
de the possibility of a transient viral infection ini-
tiating an autoimmune response by inducing
transient muscle injury, MHC expression and pre-
sentation of auto-antigens by myofibres, or on the
basis of molecular mimicry.133 Evidence that viral
infections may trigger sIBM comes from the repor-
ted development of IBM-like phenotypes in cases
of retroviral infections including HTLV134 and HIV.135
In conclusion, the aetiopathogenesis of sIBM is
still an unsolved mystery and there is a need to de-
velop better animal models of sIBM in which the
relationship between the inflammatory, degene-
rative and mitochondrial components of the dise-
ase, as well as the differential vulnerability of dif-
ferent muscle groups and the interaction with ge-
netic and environmental factors can be more cri-
tically investigated.
Histopathology
Reflecting its aetiopathogenesis, sIBM is characte-
rised by the combination of several histologic pat-
terns (Figure 1). Firstly the inflammatory compo-
nent that largely mimicks the tissue pattern in PM,
which includes upregulation of MHC class I, infil-
trates of predominantly CD8+ cytotoxic T-cells in-
vading non-necrotic muscle fibres, and the upre-
gulation of T-cell specific metalloproteinases-di-
sintegrins (ADAMs) proteins, namely ADAMs 17
and 19.136 Because of the high similarity in immu-
ne related components between PM and sIBM,
their histological differentiation may be challen-
ging. Moreover there seems to be no major diffe-
rences in the expression of subtypes of macropha-
ges between sIBM and PM137 and inflammation can
be a myopathologic feature not only of sIBM, PM
and DM, but also of other muscle diseases, such as
toxic myopathies or limb girdle muscular dystrop-
hies (Table I).138
Mitochondrial abnormalities are also a myopa-
thologic feature of sIBM. These may include rag-
ged-red fibres (abnormal fibres showing a periphe-
ral rim of red material when stained with trichro-
me, caused by the subsarcolemmal aggregation of
mitochondria), dense peripheral staining for the
activity of succinate dehydrogenase (SDH) (a mi-
tochondrial enzyme involved in the tricarboxylic
acid cycle) and, more often, myofibres devoid of
COX activity or with partial COX deficiency. Howe-
ver, even some of these features may be rarely
found in PM.139
From the outset, there may be signs of chroni-
city characterised by hypertrophic, atrophic and
split fibres with internal nuclei and increased con-
nective tissue, indicating that the disease process
has begun long before the patient seeks medical 
attention. Myopathic features such as variation in
fibre diameters, necrosis and regeneration of mus-
cle fibres are all non-specific findings.
Finally, the myopathologic degenerative featu-
res are defined by autophagic/rimmed vacuoles
and aggregates of proteins termed “inclusions”.
Rimmed vacuoles contain basophilic granular de-
posits, consisting of membranous whorls, around
the edges, and may show activation of the lysoso-
mal marker enzyme acid phosphatase. The vacuo-
les themselves usually do not contain the sIBM
characteristic inclusions18,85 but, rather, membra-
nous debris. They are lysosomal and an end-result
of muscle-fibre destruction. Recently it was repor-
ted that sIBM vacuolated muscle fibres, and other
vacuolar myopathies, contain a marker of autop-
hagosomes (autophagy protein LC3), but only in
sIBM is it colocalized with βAPP,140 suggesting that
sIBM muscle fibres may be attempting through the
autophagosome to degrade βAPP, perhaps bound
to other simple or complex proteins.
The two major types of proteinaceous inclusions
present in sIBM muscle fibres are, first, the roun-
ded, plaque-like aggregates comprising predomi-
nantly β-amyloid and, second, the “squiggly”, line-
ar deposits of various sizes, comprising
phosphorylated tau. In a given section of a sIBM
muscle biopsy, the aggregates are present mainly in
the vacuole-free cytoplasmic regions of vacuolated
muscle-fibres and in the cytoplasm of “nonvacuo-
lated” fibres. Phosphorylated tau-containing paired
helical filaments (that can be immunostained us-
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Figure 1. Histological examination of muscle biopsies from patients with inclusion body myositis reveals abnormalities 
of varying severity. In haematoxylin and eosin stained sections there may be variation in fibre diameter (A) and fibre
necrosis (arrow in A).Vacuoles rimmed by basophilic granular material are seen (arrows in B) and these are sometimes 
associated with hyalinised eosinophilic inclusions (arrow in C). Fibre necrosis can be confirmed using the acid phosphatase
histochemical preparation (D). Fibres lacking cytochrome oxidase activity may be present (arrow in E).There is
widespread expression of MHC Class I at the sarcolemma (F). Lymphocytic infiltrates are largely endomysial and are 
composed predominantly of CD8 expressing cells (G) which infiltrate into intact myofibres (arrow in H).
A-C: haematoxylin and eosin; D: acid phosphatase histochemistry; E: cytochrome oxidase histochemistry; F: MHC class I
immunohistochemistry; G-H CD8 immunohistochemistry. Bar in A represents 25µm in A-D & H, and 50µm in E-G.
A B
C D
E F
G H
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ing the SMI-31 antibody141,142) may be seen within
nuclei as loosely arranged aggregates of tubulofila-
ments, and, more frequently, similar and more den-
sely packed aggregates of tubulofilaments within
the sarcoplasm, often in the vicinity of autophagic
vacuoles. The most prominent protein accumula-
ting in muscle fibres in sIBM, β-amyloid, is recog-
nizable as small haphazardly deposited filaments
which, when forming aggregates, display congop-
hilia enhanced by Texas red-type fluorescence mi-
croscopy when using the Congo red stain, but also
stain with crystal violet and Thioflavin S. 
Temiz et al143 have recently compared muscle
biopsy features of sIBM, polymyositis with mito-
chondrial pathology (which can be hypothesised
as a variant belonging to the same disease spec-
trum as sIBM) and steroid-responsive polymyosi-
tis. Interestingly they found that αB-crystallin and
the above referred marker of autophagy LC3 were
common in sIBM and polymyositis with mito-
chondrial pathology (but not in steroid-responsi-
ve polymyositis), and that SMI-31 and TDP-43 po-
sitive aggregates were common in sIBM (but not in
polymyositis with mitochondrial pathology or ste-
roid-responsive polymyositis). β-amyloid showed
no differences in aggregates among the three
groups and, among patients with polymyositis
with mitochondrial pathology, the ones with more
rapidly progressive weakness also had more COX-
-negative muscle fibres. TDP-43 (TAR DNA bin-
ding protein-43) inclusions in sIBM have also been
described as being usually ubiquitin negative and
co-localized with T-cells at sites of inflammatory
infiltrates.144
As previously discussed, a great number of pro-
teins aggregate in sIBM muscle fibres. Some of
them are common to myofibrillar myopathies and
the same methods can be used for immunocyto-
chemical staining.145,146 Similarly, proteins of the
ubiquitin proteasome pathway of extralysosomal
protein degradation are upregulated147 and ubiqui-
tin staining is also a sensitive method for showing
the muscle fibre inclusions.92 Finally, small angu-
lated fibres are often encountered in sIBM muscle
specimens, suggesting a subtle neurogenic com-
ponent of denervation, but large group atrophy
and fibre type grouping (features of reinnervation)
are absent. Such angulated atrophic muscle fibres
display increased histochemical activity of acid
phosphatase and of the oxidative enzymes NADH
and MAG. Matrix metalloproteinases (MMP) 2, 7
and 9 have been shown in muscle fibres, inflam-
matory cells, and vessel walls.148-150
Electron microscopy (Figure 2) reveals accumu-
lation of 15-21 nm tubulofilamentous inclusions
and cytoplasmic collections of 6-10 nm amyloid-
-like filaments that immunoreact with various amy-
loid protein related antibodies.151 Abnormal myonu-
clei with intranuclear 7 nm-wide filaments are also
detected in up to 3.5% of the nuclei, but their signi-
ficance in vacuolar formation remains unclear.
It should be highlighted that a vacuolar myo-
pathy displaying similarities with sIBM can be
found in other diseases, namely the above menti-
oned hIBM, some of the distal myopathies, oculo-
pharyngeal muscular dystrophy, Emery-Dreifuss
muscular dystrophy, and even in chronic neuroge-
nic conditions such as old poliomyelitis or chronic
spinal muscular atrophy.81,82,138,152,153
Clinical manifestations and investigations
Clinical features
The hallmark of idiopathic inflammatory myopathi-
es is a progressive muscle weakness, with retained
reflexes and without sensory disturbances. sIBM,
however, is characterised by male predominance11,12
and causes weakness and atrophy of the distal and
proximal muscles. Involvement of quadriceps femo-
ris and deep finger flexors are clues to early diagno-
sis.154 Patients often present with falls because their
knees collapse owing to quadriceps muscle we-
akness, or with difficulty performing certain tasks,
such as turning keys, tying knots and holding golf
clubs, owing to weakness of finger flexors. Weakness
in sIBM may be accompanied by myalgia in up to
40% of cases155 and swallowing difficulties in the
Table I. Muscle diseases with potential 
myopathologic inflammatory features138
• Polymyositis
• Dermatomyositis
• Inclusion body myositis
• Statin myopathy
• Facio-scapulo-humeral muscular dystrophy
• Dystrophinopathy
• Dysferlinopathy
• Caveolinopathy
• Calpainopathy
• Merosinopathy
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course of the disease are common, having been re-
ported in up to 60% of patients.10
Twelve papers have described the clinical featu-
res of between 15 and 78 sIBM patients. Nine of
these studies were retrospective and based on re-
view of the medical records6,8,22,143,155-159 and three
were cross-sectional in design.9,10,160
Weakness at the time of diagnosis was reported
to be more severe in the lower than in the upper ex-
tremities,155,157 and to be more or equally severe in
proximal muscles compared with distal.155,156,158 If
weakness was described for specific muscle
groups, a different distribution emerged: the knee
extensors were considered more affected than the
hip flexors and the wrist and finger flexors were
more affected than the shoulder abductors.6 This
pattern has been confirmed by several studies, re-
vealing the finger flexors to be most severely affec-
ted, along with the knee extensors and foot dorsi-
flexors.8,9,158,160 With regard to the least affected mus-
cles each study showed a different pattern.9,160 Pro-
minent side-to-side differences have been noted,
particularly in the distal muscle groups.160
The rate of progression, the mean decrease in
muscle strength corrected for observed time, vari-
ed from 3.5%8 to 15.6 % per year158 in retrospective
studies and was found to be 7.8% per year in a small
prospective study.161 In one of the larger studies,10
time of onset of symptoms was generally after the
age of 40 (although 20% before the age of 50 years).
Patients with sIBM usually present after several
years of gradually worsening muscle weakness and
those who are untreated or who do not respond to
treatment become gradually weaker over a period
of years. Peng et al 159 assessed diseased progressi-
on in 78 patients and found that the older the age
at onset of the disease, the more rapid is the loss of
strength and function. Patients presenting before
age 60 progress to the use of a walker after an ave-
rage of 10.2 years and those presenting after age 60
require a walker after only 5.7 years of disease.159 By
15 years, most patients require assistance with ba-
sic daily activities, and some become wheelchair
bound or bedridden.
sIBM can be an indirect cause of death due to
respiratory failure or infection, particularly respi-
ratory tract infections. Subacute respiratory failu-
re requiring mechanical ventilation was recently
reported in one patient with sIBM.162 Although
most patients have a progressive loss of strength,
approximately one-third remain stable or impro-
ve when observed for a period of six months.161
Laboratory abnormalities
Muscle enzymes are typically normal or mildly ele-
vated in sIBM, with creatine kinase (CK) levels ge-
nerally being less than 10-12 times normal.10,22
Markers of systemic inflammation, such as eleva-
tion of C-reactive protein, erythrocyte sedimenta-
tion rate and anaemia, are usually absent. There
are no sIBM specific autoantibodies, although
nonspecific positive serum serologies are often
present (44% of a total of 99 patients in a study by
Koffman et al,163 and 32% of a total of 38 patients
in a study by Brower et al,163 18% of which were
myositis specific autoantibodies).
Electromyography
Electromyography (EMG) in sIBM reveals myopa-
thic patterns with increased insertional activity, fi-
brillations, and polyphasic potentials. These fin-
Figure 2. Ultrastructural examination of muscle fibres
demonstrates whorled membranous debris (arrow in A)
and associated randomly orientated filaments (B). Bar in A
represents 700nm in A and 200nm in B.
A
B
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dings are not specific for sIBM and are present in
other inflammatory myopathies. In some cases,
however, a mixed pattern of myopathic and neu-
rogenic changes is seen and that has been descri-
bed as more typical of sIBM than PM.22,155,157,164 Ner-
ve conduction studies are usually normal.
Magnetic resonance imaging
There have been reports of MRI use to characteri-
se inflammation in cases of sIBM,68,165-169 which
have concentrated mostly on imaging the thigh
muscles. Papers have emphasised the sensitivity of
MRI when using fat-suppressed imaging techni-
ques to detect inflammation, and similarly the va-
lue of recognizing the distribution of changes in
helping to predict the cause of myopathy or to
identify sites of inflammation, confirmed at sub-
sequent biopsy.170-172 However, MRI findings may
not be specific and therefore images should be re-
viewed in conjunction with clinical information.173
Phillips et al 9 evaluated 9 patients with sIBM
using quantitative and manual muscle testing as
well as MRI. They found that weakness of the qua-
driceps femoris and the forearm flexors was present
in most patients, but there was considerable vari-
ability in the patterns and severity of muscle invol-
vement. Sekul et al 169 had previously reported a
selective involvement of the flexor digitorum pro-
fundus that might occur early in the course of the
disease and could be easily demonstrated by MRI
in up to 95% of patients. Because selective flexor di-
gitorum profundus involvement appeared to be a
very frequent and characteristic finding in patients
with sIBM, MRI of the forearm was proposed by
these authors to be a useful noninvasive test in
supporting the diagnosis of sIBM. MRI may also
help to evaluate the extent and number of muscle
lesions and eventually to follow their evolution un-
der therapy.173
The role of MRI in sIBM is therefore still to be
clarified and the question calls for longitudinal
MRI studies with clinical-MRI correlation. MRI
may prove to be a very helpful diagnostic and as-
sessment tool in sIBM and its results may even in-
corporate future diagnostic criteria if proven to be
robust and reproducible.
Classification criteria for sIBM
The criteria for the diagnosis of sIBM were first
proposed by Griggs and colleagues in 1995,7 with
minor modifications made by Tawil and Griggs in
2002174 and again changes proposed by Needham
and Mastaglia in 2007.175 The criteria have evolved
to incorporate some additional biopsy features
(such as expression of MHC-I and COX-negative fi-
bres) and the recognition that some of the histolo-
gical findings (such as rimmed vacuoles and con-
gophilic inclusions) are probably absent in many
biopsies taken in the earlier stages of the disease.
Table II describes the Needham and Mastaglia
diagnostic criteria as well as the characteristic fea-
tures and reported associated disorders for sIBM.175
Some patients with clinical features of sIBM lack
the canonical pathologic features of the disease
even on repeated muscle biopsies6,176,177 and the ab-
sence of the late findings in patients with a typical
clinical phenotype does not exclude the diagnosis
of sIBM.1,178 Future studies of sIBM are warranted
in order to evaluate the performance and clinical
impact of these classification systems.
Treatment
Despite the apparent involvement of primary im-
mune factors in the pathogenesis of sIBM, this di-
sease remains resistant to most immunotherapies.
At present, sIBM remains a disabling disease, with
most patients requiring an assistive mobility devi-
ce within 5 to 10 years of onset.159,161 Although the
common immunotherapeutic agents are generally
ineffective and there is no established therapy to
stop the progression of the disease,179 some pati-
ents have, anecdotally, responded to these thera-
pies to a certain extent. The protracted disease
course has meant that few trials have been of ade-
quate duration or have had sufficient power to de-
tect even sizeable treatment effects. Moreover,
sIBM is often diagnosed years after the onset of
symptoms, when muscle damage may be so ad-
vanced as to prevent any improvement in strength
even if the disease process can be arrested. There-
fore, there are insufficient data to enable an eviden-
ce-based approach to treatment, which is still lar-
gely empirical and varies considerably in different
centres.180 It has been estimated that in order to
demonstrate a significant effect from treatment for
sIBM in a placebo-controlled study, 200 subjects
would need to be enrolled in a six-month study or
100 in a year-long trial.179 This estimate should be
kept in mind when considering the data on efficacy
of treatment presented below.
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Corticosteroids
Corticosteroids alone appear to have a limited role
in patients with sIBM,22,157,181-183 with the results of
several uncontrolled trials showing stabilisation or
temporary improvement in muscle strength in
some patients, which is usually not maintained. 
Barohn et al 181 conducted a 12-month prospec-
tive trial that included 8 patients with sIBM trea-
ted with high-dose oral prednisolone. Although the
serum CK level fell, muscle strength worsened af-
ter prednisone treatment. In addition, the num-
ber of vacuolated and amyloid-positive fibres in-
creased, despite a reduction in the numbers of T
cells.
Lotz et al 22 reported that muscle strength conti-
nued to deteriorate in 25 sIBM patients followed for
Table II. Proposed diagnostic criteria for sIBM7,174,175
Characteristic features
Clinical features
• Duration of illness >6 months
• Age at onset >30 years
• Slowly progressive muscle weakness and atrophy: selective pattern with early involvement of quadriceps femoris
and finger flexors, although can be asymmetric
• Dysphagia is common
Laboratory features
• Serum creatine kinase concentration might be high but can be normal
• Electromyography: myopathic or mixed pattern, with both short and long duration motor unit potentials and
spontaneous activity
Muscle biopsy
• Myofibre necrosis and regeneration
• Endomysial mononuclear cell infiltrate (of variable severity)
• Mononuclear cell invasion of non-necrotic fibres: predominately CD8+ T cells
• MHC class I expression in otherwise morphologically healthy muscle fibres
• Vacuolated muscle fibres (rimmed vacuoles)
• Ubiquitin-positive inclusions and amyloid deposits in muscle fibres
• Nuclear and/or cytoplasmic 16-20 nm filamentous inclusions on electron microscopy
• COX-negative fibres (excessive for age)
Associated disorders
Inclusion body myositis usually occurs in isolation, but can be associated with:
• Other autoimmune disorders or connective tissue diseases (common variable immunodeficiency, idiopathic 
thrombocytopenic purpura, celiac sprue, Sjögren´s syndrome, dermatomyositis, systemic lupus erythematosus,
systemic sclerosis, rheumatoid arthritis, paraproteinaemia, autoantibodies)
• Occasional: HIV, HTLV-I, and hepatitis C infection
• Rare: toxoplasmosis, sarcoidosis, post-poliomyelitis, macrophagic myofasciitis 
Diagnostic categories
Definite inclusion body myositis
• Characteristic clinical features, with biopsy confirmation: inflammatory myopathy with autoaggressive T cells,
rimmed vacuoles, COX-negative fibres, amyloid deposits or filamentous inclusions and upregulation of MHC-I
expression.The presence of other laboratory features are not mandatory if the biopsy features are diagnostic
• Atypical pattern of weakness and atrophy but with diagnostic biopsy features
Probable inclusion body myositis
• Characteristic clinical and laboratory features but incomplete biopsy criteria - e.g., features of necrotising 
inflammatory myopathy with T cell invasion of muscle fibres but absence of rimmed vacuoles, amyloid deposits,
filamentous inclusions, and COX negative fibres
Possible inclusion body myositis
• Atypical pattern of weakness and incomplete biopsy criteria
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at least two years and treated with prednisone at
dose levels frequently effective in PM. Joffe et al 183
also reported that patients with sIBM had poor res-
ponses to prednisone.
Some reports have noted a partial response to
corticosteroids with either mild improvement in or
stabilization of muscle strength.157,182 Serum CK le-
vels often fall and may even normalize with corti-
costeroid therapy, however, this biochemical res-
ponse did not predict clinical benefit.182
There is one apparent exception to the usually
limited response to corticosteroids. Patients with
sIBM coexistent with other connective tissue di-
seases (Sjögren’s syndrome, systemic lupus erythe-
matosus and the rash of DM) may have a clinically
important benefit from steroid therapy but it re-
mains uncertain whether any of this benefit re-
flects a specific improvement in their sIBM featu-
res.155,184,185
Cytotoxic drugs
Methotrexate and azathioprine, alone or in com-
bination, have shown at best minor benefit, with
apparent stabilisation or improvement over short
periods.155,157,182,186 However, the largest trial, a ran-
domized study of 44 patients who received either
weekly methotrexate or placebo for 48 weeks186
showed that there was no significant difference in
muscle strength between the two groups, although
the serum CK levels decreased significantly in the
methotrexate group.
Limited reported experience with cyclo-
phosphamide and chlorambucil has also not been
encouraging.187 Mycophenolate has been benefi-
cial on occasion.188 However, none of these drugs
has been assessed in controlled clinical trials. 
As with corticosteroids, plasma CK levels often
fall and may even normalize with immunosup-
pressive treatment but the biochemical response
does not predict clinical benefit.182,186
Intravenous immunoglobulin
The efficacy of intravenous immunoglobulin
(IVIG) has been evaluated in two small open se-
ries189,190 and three double blind studies.191-193 but
all of the last trials have been of short duration (two
lasted 3 months, and one lasted 6 months).190,192,193
In the first uncontrolled study, improvement in
muscle strength and functional status was noted in
three of four patients after the second monthly in-
fusion.189 These results were not replicated in an
unrandomized, open-label study with nine pa-
tients who showed no clinical improvement.190
In a double-blind, placebo-controlled crosso-
ver study involving 19 patients, no statistically sig-
nificant improvement in overall muscle strength
due to IVIG was observed. However, there was a
trend toward improvement during IVIG treatment,
and nine of the patients continued IVIG therapy in-
dependently after the study was concluded becau-
se of a sense of improved quality of life.192
A double-blind study by Dalakas et al,191 ran-
domly assigned 36 patients to either IVIG (month-
ly infusions for 3 months) or placebo infusions; be-
fore infusions, all patients also received high dose
prednisone for 3 months. When compared to ba-
seline, there were no significant differences in mus-
cle strength during 4-months of observation. Fol-
low-up biopsies in 24 random patients revealed a
greater reduction in the number of necrotic myo-
fibres in those who received IVIG than placebo, but
this appeared to be of no clinical significance. The
authors concluded that the combination of pred-
nisone and IVIG for a 3-month period was not ef-
fective in sIBM. 
In the longer (6 month) crossover trial by Walter
et al,193 disease progression stopped in 18 of 22 pa-
tients, although muscle strength scores, symptoms
and myographic test results did not change signi-
ficantly.
At the present time, IVIG cannot be recommen-
ded because it has shown, at best, only very mo-
dest benefit. Trials of longer duration (at least 12
months), sufficiently powered in terms of num-
bers of patients and including patients with early
disease (hypothetically more responsive to treat-
ment) are warranted to determine the role of IVIG
in sIBM.
One exception may be the use of IVIG in the
treatment of dysphagia. In one report, four patients
with severe dysphagia due to upper esophageal
dysfunction all recovered swallowing function 
after treatment with 6 to 8 monthly infusions of
IVIG.194 In patients with severe dysphagia, bougie
dilation, cricopharyngeal myotomy,195 or botuli-
num toxin injection into the upper oesophageal
sphincter196 may be alternative solutions.
New biologic agents 
New biologic agents targeting presumed immuno-
pathological processes such as T cell proliferation,
transmigration, antigen recognition or endoplas-
mic reticulum stress, might produce more rewar-
ding results.
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A 6 month randomised, placebo-controlled 
trial of interferon-beta 1a (30 µg/week) in a group
of 30 patients with sIBM did not show an improve-
ment in muscle strength or mass.197 A subsequent
trial of a higher dose (60 µg/week) was also inef-
fective.198 However, a substantial clinical improve-
ment was reported with interferon-beta treatment
in a Japanese patient with sIBM who was a carrier
of hepatitis C.199
A pilot trial of the TNFα-blocker etanercept did
not find an improvement in composite muscle
strength scores at 6 months, although there was a
slight improvement in grip strength after 12
months of treatment.200
The results of a 12-month, open, randomized
trial in 11 sIBM patients using anti-T-lymphocyte
globulin and methotrexate have been encouraging:
those treated with antithymocyte globulin and me-
thotrexate had not only a substantial fall in serum
CK levels but also a significant increase in muscle
strength of 1.4% compared with a mean loss of
strength of 11.1% in the methotrexate alone
group.201
Dalakas has recently reported in abstract for-
mat the results from a trial with alemtuzumab (a
humanized T-cell-depleting monoclonal antibody
against CD52) in the treatment of sIBM patients,
and these have also been encouraging.202 In this
trial, 13 sIBM patients with a 12-month natural his-
tory were treated with 0.3 mg/kg/day alemtuzu-
mab for 4 days. Primary end-points were the disea-
se stabilization or increased strength 6 months af-
ter treatment. Alemtuzumab significantly reversed
disease progression up to six months, improved
the strength of some patients, and reduced the in-
flammatory and degeneration-associated molecu-
les in the patients’ muscles.202
Other promising agents include sirolimus (ra-
pamycin), which acts via a calcineurinin depen-
dent pathway to prevent the translation of mRNA
for key cytokines, and natalizumab, which blocks
the transmigration of T cells across the endotheli-
al cell wall.203
Anti-degeneration and anti cell-stress therapies
Agents that interfere with degeneration and endo-
plasmic reticulum stress might protect the myofi-
bre from chronic deleterious stimuli. At the trans-
lational level, Kitazawa et al 114 tried lithium, a drug
increasingly explored as a neuroprotective agent,
because it can modulate tau phosphorylation or
amyloid processing. The results, although disap-
pointing in their model, were informative. Lithium
inhibited tau phosphorylation, but did not signifi-
cantly affect the motor function of the treated ani-
mals and had no effect on IL-1β or the intramus-
cular production of β-amyloid, suggesting that
amyloid formation and inflammation occur
upstream to tau pathology. 
A subset of new non-steroidal anti-inflamma-
tory drugs are potent modulators of γ-secretase,204
reducing amyloid production, and may also be
candidates for clinical testing in sIBM.
Arimoclomol, an investigational drug for amyo-
trophic lateral sclerosis, might be a candidate for
use in sIBM. By prolonging the activity of the tran-
scription factor, heat shock factor-1 (HSF-1), the
compound has been shown to amplify heat shock
protein (HSP) gene expression. Arimoclomol, the-
refore, it further elevates the HSP levels already in-
duced by cellular stresses, a response which appe-
ars to be attenuated with advanced age.205-207 HSPs
have been shown to attenuate protein misfolding
and aggregation promoting cellular defences
against such processes.112 Via inhibition of the pro-
inflammatory transcription factor NFkB, they have
also been shown to dampen inflammatory respon-
se. More studies of anti-degeneration and anti cell-
stress therapies in sIBM are warranted.
Other empirical therapies
Oxandrolone (a synthetic androgen) showed a bor-
derline significant effect on isometric muscle
strength in an 8 month double-blinded, crossover
trial.208 Despite the lack of controlled clinical trials,
clenbuterol (a β-agonist), coenzyme Q10 (ubiqui-
none), carnitine, and antioxidants have been re-
commended on empirical grounds175 and might
provide symptomatic benefit in some patients. 
Exercise therapy
It has previously been thought that exercise pro-
grams should be avoided in patients with inflam-
matory myopathies because of concern that the
exercise could aggravate the underlying inflamma-
tory process.209 However, studies in other forms of
idiopathic inflammatory myopathies, such as PM
and DM, showed a positive response to physical
training and the absence of an adverse effect on the
disease process.210,211 Furthermore, studies with pa-
tients with sIBM using strength and aerobic trai-
ning concluded that exercise can be performed sa-
fely, can lead to dynamic strength improvements,
and possibly can help preventing continued loss of
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muscle strength.212,213 A more recent study214 has
shown that a closely monitored, 16-week, home-
based, individualized functional exercise program
can lead to significant gains in muscle strength and
improvements in the performance of functional
tasks in patients with sIBM. The protocol was well
tolerated by all the patients and did not cause 
adverse muscle symptoms or elevation of serum
CK levels.
Conclusion
sIBM is a complex and disabling disorder. Many of
its mysteries are still unsolved. Larger, multicentre
trials are needed to correctly define the epidemio-
logy and natural history of sIBM. The identificati-
on of susceptibility genes will be important to elu-
cidate its pathogenesis and to provide clues to the
development of targeted therapies. Understanding
the interplay between inflammation and degene-
ration and elucidating the molecules that drive
muscle degeneration will be crucial steps. That is
not an easy task, and additional animal models are
required, but significant advances have been made
in the last few years. There is also an urgent need
for new trials of adequate duration, sufficient po-
wer and including patients with early disease. Se-
veral therapeutic agents are already in the pipeli-
ne. The recent clues and the growing interest of the
scientific community in unravelling all these
mysteries allows us to have great hopes in impro-
ving the quality of care for patients with sIBM in a
near future.
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